Endovascular Today: Preclinical Study Evaluates Primary Lesion Treatment With CSI’s Orbital Atherectomy System Before Drug Delivery in Calcified PAD

May 20, 2015—CBSET, a preclinical biomedical research institute, announced findings from a cadaver study suggesting that modification of atherosclerotic plaque with the Diamondback 360 orbital atherectomy system (Cardiovascular Systems, Inc. [CSI]) improved drug uptake in calcified peripheral lesions. Gunnar Tepe, MD, from RoMed Hospital in Rosenheim, Germany, stated in CBSET’s announcement, “This preclinical study could have a significant clinical impact by demonstrating improved drug delivery after modification of calcified lesions.”

The study results were presented by CBSET Chairman Elazer Edelman, MD, in a dedicated session on peripheral interventions at the EuroPCR 2015 conference held May 19–22 in Paris, France.

In a separate press release, CSI specified the findings showed that primary treatment with CSI’s Diamondback 360 improved paclitaxel absorption by 50% in the calcified cadaveric peripheral arteries. Historically, noted the company, calcified plaque barriers in arteries have been reported to make drug diffusion and retention more difficult.

Read full article in Endovascular Today.